Literature DB >> 22850410

A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors.

Ting Gui1, Dongyan Cao, Keng Shen, Jiaxin Yang, Yiwen Zhang, Qi Yu, Xirun Wan, Yang Xiang, Yu Xiao, Lina Guo.   

Abstract

OBJECTIVE: To evaluate the clinicopathological features of ovarian Sertoli-Leydig cell tumors (SLCTs) and to explore the reasonable therapy.
METHODS: A total of 40 cases of SLCTs were retrospectively reviewed.
RESULTS: The incidence of SLCTs was 0.41%, with a median age of 28 years. All tumors were confined to one ovary. Four tumors were well differentiated, 14 were intermediately differentiated, 20 were poorly differentiated, and 2 were undefined; 2 cases had heterologous elements, and 3 had a retiform pattern. The patients were classified into 3 groups: androgen excess (25/40), estrogen excess (6/40), and no endocrine changes (9/40). The percentages of tumors >10 cm in diameter were 8.0%, 16.7% and 40.0%, respectively; the percentages of poor differentiation were 40.0%, 50.0% and 77.8%, respectively; and the percentages of tumor rupture were 20.0%, 16.7% and 66.7%, respectively. One patient underwent cystectomy, 27 underwent unilateral salpingo-oophorectomy, and 12 underwent total hysterectomy and bilateral salpingo-oophorectomy. A total of 23 patients received postoperative chemotherapy. One patient died of diabetic nephropathy, and 3 were lost to follow up. The remaining 36 were followed up from 12 to 377 (average 70.4) months. Two patients with stage Ic tumors of poor differentiation had a recurrence within 13 and 21 months, and both obtained complete remission after the second surgery and chemotherapy.
CONCLUSIONS: The prognosis of SLCTs is good, although poorly differentiated tumors may recur. Conservative surgery is acceptable for young patients wishing to preserve fertility, and postoperative adjuvant chemotherapy and long-term follow up are recommended to those with high-risk factors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22850410     DOI: 10.1016/j.ygyno.2012.07.114

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

1.  Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors.

Authors:  Zhen Yuan; Xiao Huo; Dezhi Jiang; Mei Yu; Dongyan Cao; Huanwen Wu; Keng Shen; Jiaxin Yang; Ying Zhang; Huimei Zhou; Yao Wang
Journal:  Oncologist       Date:  2020-08-11

2.  Endocrine pathology of the ovary : in tribute to Robert E Scully, MD.

Authors:  Esther Oliva; Robert H Young
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 3.  Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature.

Authors:  Longwen Chen; Cairo Dana Tunnell; Giovanni De Petris
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

4.  Clinicopathologic features of ovarian Sertoli-Leydig cell tumors.

Authors:  Hai-Yan Zhang; Jia-Er Zhu; Wen Huang; Jin Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

Review 5.  Ovarian Sertoli-Leydig cell tumor with heterologous elements of gastrointestinal type associated with elevated serum alpha-fetoprotein level: an unusual case and literature review.

Authors:  Mariana Horta; Teresa Margarida Cunha; Rita Canas Marques; Ana Félix
Journal:  J Radiol Case Rep       Date:  2014-11-30

6.  Poorly Differentiated Sertoli-Leydig Cell Tumour of Ovary with Heterologous Elements.

Authors:  Tapan Kumar Sahoo; Tushar Kar; Asaranti Kar; Sasmita Panda
Journal:  J Clin Diagn Res       Date:  2017-05-01

7.  Fertility-sparing management and obstetric outcomes in a 20-year-old patient with a Sertoli-Leydig cell tumor of the ovary: A case report and review of the literature.

Authors:  Thomas Stavrakis; Ioannis Kalogiannidis; Stamatios Petousis; Chrisoula Tsompanidou; Dimitris Delkos; Nikolaos Prapas; David Rousso
Journal:  Oncol Lett       Date:  2016-06-09       Impact factor: 2.967

8.  Ovarian Sertoli-Leydig cell tumors: MRI findings and pathological correlation.

Authors:  Song-Qi Cai; Shu-Hui Zhao; Jin-Wei Qiang; Guo-Fu Zhang; Xue-Zhen Wang; Li Wang
Journal:  J Ovarian Res       Date:  2013-10-26       Impact factor: 4.234

9.  Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.

Authors:  Sebastien Gouy; Alexandra Arfi; Amandine Maulard; Patricia Pautier; Enrica Bentivegna; Alexandra Leary; Cyrus Chargari; Catherine Genestie; Philippe Morice
Journal:  Oncologist       Date:  2018-09-10

10.  Uncommon indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Francis Zheng Yi Yee; Grace Hwei Ching Tan; Claramae Shulyn Chia; Khee Chee Soo; Melissa Ching Ching Teo
Journal:  Pleura Peritoneum       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.